DIV-TREX

DIV-TREX is an experimental anticancer therapeutic strategy being developed by Divincell that is described in public materials as enabling **targeted correction of KRAS oncogene mutations**. Available project summaries indicate that the program is intended for KRAS-driven solid tumors and has shown preclinical antitumor activity, including tumor growth arrest, tumor regression, and potential synergy with existing cancer treatments in pancreatic, lung, and colorectal tumor models. Publicly accessible information remains limited, and the precise therapeutic modality, molecular construct, specific mechanism details, route, and formulation have not been clearly disclosed in authoritative sources.